New combo therapy aims to keep head and neck cancer from coming back

NCT ID NCT07535567

Not yet recruiting Disease control Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University Source: ClinicalTrials.gov ↗

First seen Apr 23, 2026 · Last updated May 01, 2026 · Updated 1 time

Summary

This study looks at whether adding the drug benmelstobart to standard treatment (radiation plus nimotuzumab) can help prevent head and neck cancer from returning after surgery. About 386 adults with intermediate-risk features will be randomly assigned to one of two groups. The main goal is to see if the new combination improves how long patients stay cancer-free.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

HEAD AND NECK SQUAMOUS CELL CARCINOMA HEAD AND NECK SQUAMOUS CELL CARCINOMA